{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:22Z","timestamp":1788262162340,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ejca.2014.10.007","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T21:29:07Z","timestamp":1414186147000},"page":"3206-3211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Growth deceleration in children treated with imatinib for chronic myeloid leukaemia"],"prefix":"10.1016","volume":"50","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Mazingue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"V\u00e9rit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Berthou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Galambrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Yacouben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chastagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gandemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Reguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Couillault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tackwa","family":"Khalifeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rialland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2014.10.007_b0005","series-title":"Cancer incidence and survival among children and adolescents: United States SEER Program 1975\u20131995","first-page":"17","article-title":"Leukemias","author":"Smith","year":"1999"},{"issue":"20","key":"10.1016\/j.ejca.2014.10.007_b0010","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2014.10.007_b0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.10.007_b0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.V112.11.186.186","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2014.10.007_b0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.ejca.2014.10.007_b0030","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2014.10.007_b0035","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","article-title":"Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib","volume":"105","author":"Dewar","year":"2005","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ejca.2014.10.007_b0040","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Eng J Med"},{"issue":"3","key":"10.1016\/j.ejca.2014.10.007_b0045","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2014.10.007_b0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","article-title":"Growth deceleration in a girl treated with imatinib","volume":"89","author":"Kimoto","year":"2009","journal-title":"Int J Hematol"},{"issue":"9633","key":"10.1016\/j.ejca.2014.10.007_b0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":"Low bone density and decreased inhibin-B\/FSH ratio in a boy treated with imatinib during puberty","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2014.10.007_b0060","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ejca.2014.10.007_b0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2014.10.007_b0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"issue":"22","key":"10.1016\/j.ejca.2014.10.007_b0075","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V114.22.863.863","article-title":"Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French national phase IV trial (ASH annual meeting abstract)","volume":"114","author":"Millot","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2014.10.007_b0080","series-title":"Auxologie, M\u00e9thodes et s\u00e9quences","author":"Semp\u00e9","year":"1979"},{"issue":"5","key":"10.1016\/j.ejca.2014.10.007_b0085","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia","volume":"59","author":"Rastogi","year":"2012","journal-title":"Ped Blood Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2014.10.007_b0090","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejca.2014.10.007_b0095","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia","volume":"93","author":"J\u00f6nsson","year":"2008","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ejca.2014.10.007_b0100","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/pbc.24397","article-title":"Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis","volume":"60","author":"Narayanan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2014.10.007_b0130","first-page":"20","article-title":"TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal mode","volume":"225","author":"Ulmer","year":"2013","journal-title":"Klin Padiatr"},{"issue":"4","key":"10.1016\/j.ejca.2014.10.007_b0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pbc.22945","article-title":"Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy","volume":"56","author":"Hobernicht","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2014.10.007_b0115","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/leu.2009.150","article-title":"Imatinib mesylate causes growth plate closure in vivo","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ejca.2014.10.007_b0120","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3346\/jkms.2009.24.6.1071","article-title":"Endocrine complications after hematopoietic stem cell transplantation during childhood and adolescence","volume":"24","author":"Jug","year":"2009","journal-title":"J Korean Med Sci"},{"issue":"11","key":"10.1016\/j.ejca.2014.10.007_b0125","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914010065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914010065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T13:19:57Z","timestamp":1746451197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914010065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":25,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0959804914010065"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.10.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}